# US 2021/0275672 A1 · Compound usable as cationic lipid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275672 A1
- Document ID: US20210275672A1
- Status: Published application
- Kind: A1
- Application number: 16/336,668
- Filed: 2017-09-27
- Published: 2021-09-09
- Earliest claimed: 2016-09-27
- Assignees: Kyowa Hakko Kirin Co., Ltd.
- Applicants: Kyowa Kirin Co., Ltd.
- Inventors: Shintaro HOSOE; Hayato YABUUCHI
- Web page: https://patentgrep.com/patent/US20210275672A1

## CPC

- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- C07C 217/28: having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a compound represented by formula (I) usable as a cationic lipid that facilitates introduction of a nucleic acid, for example, into a cell, and a composition or the like containing the compound.

## Claims

### Claim 1

A compound represented by formula (I), or a pharmaceutically acceptable salt thereof:
wherein R1 and R2 are, the same or different, a hydrogen atom or C1-C3 alkyl;
A1 and A2 are, the same or different, linear or branched C8-C20 alkylene or C8-C20 alkenylene;
M1 and M2 are, the same or different, selected from the group consisting of —C═C—, —OC(O)—, —C(O)O—, —SC(O)—, —C(O)S—, —OC(S)—, —C(S)O—, —SS—, —C(R5)═N—, —N═C(R5)—, —C(R5)═N—O—, —O—N═C(R5)—, —N(RS)C(O)—, —C(O)N(RS)—, —N(RS)C(S)—, —C(S)N(RS)—, —N(R5)C(O)N(R6)—, —N(RS)C(O)O—, —OC(O)N(R5)—, and —OC(O)O—;
R5 and R6 are, the same or different, a hydrogen atom or C1-C3 alkyl; and
B1 and B2 are, the same or different, linear or branched C1-C16 alkyl or C2-C16 alkenyl.

### Claim 2 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are, the same or different, a hydrogen atom or methyl.

### Claim 3 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein A1 and A2 are, the same or different, linear or branched C8-C12 alkylene or C10-C14 alkenylene.

### Claim 4 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein M1 and M2 are, the same or different, selected from the group consisting of —C═C—, —OC(O)—, and —C(O)O—.

### Claim 5 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein B1 and B2 are, the same or different, linear or branched C2-C9 alkyl or C3-C9 alkenyl.

### Claim 6 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein B1-M1-A1 and B2-M2-A2 are, the same or different, selected from the group consisting of (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl, and (Z)-docos-13-enyl.

### Claim 7 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein B1-M1-A1 and B2-M2-A2 are, the same or different, selected from the group consisting of (Z)-hexadec-9-enyl, (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl, and (11Z,14Z)-icosa-11,14-dienyl.

### Claim 8 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof,
wherein B1-M1-A1 and B2-M2-A2 are, the same or different, selected from the following structures:
wherein n is an integer from 1 to 4.

### Claim 9 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein B1-M1-A1 and B2-M2-A2 are the same.

### Claim 10 (depends on 1)

A composition, comprising the compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a nucleic acid.

### Claim 11 (depends on 10)

The composition according to claim 10, wherein the nucleic acid is a nucleic acid having a silencing effect on a target gene through the use of RNA interference (RNAi).

### Claim 12 (depends on 11)

The composition according to claim 11, wherein the target gene is a gene related to tumor.

### Claim 13 (depends on 11)

The composition according to claim 11, wherein the target gene is a gene expressed in the liver, the lung, the kidney, or the spleen.

### Claim 14 (depends on 10)

A medicament, comprising the composition according to claim 10.

### Claim 15

(canceled)

### Claim 16 (depends on 10)

A method for introducing the nucleic acid into a cell using the composition according too claim 10.

### Claim 17 (depends on 10)

A treatment method for a disease, comprising a step of administering the composition according to claim 10 to a mammal.

### Claim 18 (depends on 17)

The treatment method according to claim 17, wherein the composition is intravenously administered.
